Japan Tobacco, Inc.
JT Bldg. 2
Toranomon 2-chome
Minato-ku
Tokyo
105-8422
Tel: 81-3-3582-3111
Fax: 81-3-5572-1441
Website: https://www.jt.com/
About Japan Tobacco, Inc.
11 articles about Japan Tobacco, Inc.
-
Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan
7/10/2019
Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan.
-
Opko Health Inks $118 Million Deal with Japan Tobacco, Inc. for Rayaldee
10/12/2017
-
Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.
4/23/2012
-
Merck & Co., Inc. Ditches Bone Drug Deal with Japan Tobacco, Inc.
10/17/2011
-
Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.
4/18/2011
-
Japan Tobacco's Novel Osteoporosis Drug Promising in Early Study
9/17/2009
-
Orphagen Pharmaceuticals Announces Collaboration And License Agreement With Japan Tobacco
1/7/2009
-
Merck & Co., Inc. (JOBS), Japan Tobacco in Osteoporosis Drug Deal
9/25/2008
-
Keryx Biopharmaceuticals Licenses Rights to Japan Tobacco; Torii Pharmaceutical Co. to Pay up to $100 Million
9/26/2007
-
Arcadia Biosciences, Inc. Licenses Corn And Rice Transformation Technology From Japan Tobacco
10/2/2006
-
Japan Tobacco And GlaxoSmithKline Conclude Licensing Agreement For New Drug Candidate
4/20/2006